NCT05434312View on ClinicalTrials.gov

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
Chronic Myelogenous Leukemia
Interventions
DRUG

TGRX-678

Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

lead

Shenzhen TargetRx, Inc.

INDUSTRY